MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 597507 | Name: Aspirin DL-lysine

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Aspirin DL-lysine, also known as lysine acetylsalicylate, is a water-soluble salt form of acetylsalicylic acid (aspirin) combined with the amino acid DL-lysine. It retains the anti-inflammatory, analgesic, antipyretic, and antiplatelet properties of aspirin but offers faster onset of action and improved gastrointestinal tolerability due to its increased solubility and buffered nature. Once administered, it rapidly dissociates into aspirin and lysine, with aspirin exerting its bioactivity by irreversibly inhibiting cyclooxygenase enzymes (COX-1 and COX-2), thereby reducing prostaglandin and thromboxane synthesis.

Chemical Structure

Aspirin DL-lysine
Aspirin DL-lysine
CAS#62952-06-1 (lysine)

Theoretical Analysis

MedKoo Cat#: 597507

Name: Aspirin DL-lysine

CAS#: 62952-06-1 (lysine)

Chemical Formula: C15H22N2O6

Exact Mass: 0.0000

Molecular Weight: 326.34

Elemental Analysis: C, 55.21; H, 6.80; N, 8.58; O, 29.41

Price and Availability

Size Price Availability Quantity
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
50-78-2 69-46-5 (calcium) 62952-06-1 (lysine)
Synonym
Aspirin DL-lysine; Aspegic; ASL; DL-Lysine acetylsalicylic acid salt; Aspisol;
IUPAC/Chemical Name
lysine compound with 2-acetoxybenzoic acid (1:1)
InChi Key
JJBCTCGUOQYZHK-UHFFFAOYSA-N
InChi Code
InChI=1S/C9H8O4.C6H14N2O2/c1-6(10)13-8-5-3-2-4-7(8)9(11)12;7-4-2-1-3-5(8)6(9)10/h2-5H,1H3,(H,11,12);5H,1-4,7-8H2,(H,9,10)
SMILES Code
NC(CCCCN)C(O)=O.O=C(O)C1=CC=CC=C1OC(C)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 326.34 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Wang C, Shi QP, Ding F, Jiang XD, Tang W, Yu ML, Cheng JQ. Reevaluation of the post-marketing safety of Xuebijing injection based on real-world and evidence-based evaluations. Biomed Pharmacother. 2019 Jan;109:1523-1531. doi: 10.1016/j.biopha.2018.10.190. Epub 2018 Nov 14. PMID: 30551404. 2: Shen Y, Hu YL, Zhang Y, Wang JM. Effects of Danshensu on maternal syndrome in phosphatidylserine/phosphatidylcholine microvesicle induced-mouse model: is it a candidate for preeclampsia remedy? Chin Med J (Engl). 2010 Apr 5;123(7):895-900. PMID: 20497684. 3: Zhou YL, Liu YJ, Fu JN, Wei W. [Effect of Huaisanzhen on central analgesic transmitters in the rat of the nerve root pain caused by protrusion of lumbar intervertebra disc]. Zhongguo Zhen Jiu. 2007 Dec;27(12):923-6. Chinese. PMID: 18271239. 4: Zhou YL, Zhang SQ, Sun GS, Chen JH, Liu P, Liu YJ, Lin GP, Hu B. [Clinical observation on ankle-three-needle for treatment of nerve root pain of prolapse of lumbar intervertebral disc]. Zhongguo Zhen Jiu. 2006 Dec;26(12):847-50. Chinese. PMID: 17313003. 5: Zhou YL, Liu YJ, Chen JH, Hu B, Zhang SQ, Sun GS. [Clinical study on analgesic effect of Huaisanzhen on the nerve root pain due to prolapse of lumbar intervertebral disc]. Zhongguo Zhen Jiu. 2005 Jan;25(1):31-3. Chinese. PMID: 16309152. 6: Kiyomoto K, Tamaki T, Tomohiro A, Nishiyama A, Aki Y, Kimura S, Abe Y. Role of nitric oxide in desmopressin-induced vasodilation of microperfused rabbit afferent arterioles. Hypertens Res. 1997 Mar;20(1):29-34. doi: 10.1291/hypres.20.29. PMID: 9101310. 7: Kamei C, Sugimoto Y, Ohishi H, Okumura Y, Kitazumi K. Epileptogenic activity induced by combined treatment with antiinflammatory drugs and enoxacin and its inhibition by a calcium antagonist, nicardipine. Methods Find Exp Clin Pharmacol. 1996 Nov;18(9):579-88. PMID: 9010832. 8: Yoshida H, Tamaki T, Aki Y, Kimura S, Takenaka I, Abe Y. Effects of angiotensin II on isolated rabbit afferent arterioles. Jpn J Pharmacol. 1994 Dec;66(4):457-64. doi: 10.1254/jjp.66.457. PMID: 7723223. 9: Imokawa S, Sato A, Taniguchi M, Toyoshima M, Nakazawa K, Hayakawa H, Chida K. [A case of aspirin-induced cough without bronchoconstriction. A new type of aspirin hypersensitivity]. Nihon Kyobu Shikkan Gakkai Zasshi. 1994 Sep;32(9):883-7. Japanese. PMID: 7799560. 10: Yasu T, Oshima S, Imanishi M, Nonogi H, Haze K, Kuramochi M, Omae T, Hayashi Y, Yamamoto S. Effects of aspirin DL-lysine on thrombin generation in unstable angina pectoris. Am J Cardiol. 1993 May 15;71(13):1164-8. doi: 10.1016/0002-9149(93)90640-x. PMID: 8480641. 11: Imokawa S, Sato A, Taniguchi M, Toyoshima M, Nakazawa K, Hayakawa H, Chida K. [A case of asthma relieved by aspirin--the first case in Japan and investigation of its mechanism]. Arerugi. 1992 Nov;41(11):1597-604. Japanese. PMID: 1492794. 12: Imanishi M, Akabane S, Takamiya M, Kawamura M, Matsushima Y, Kuramochi M, Omae T. Critical degree of renal arterial stenosis that causes hypertension in dogs. Angiology. 1992 Oct;43(10):833-42. doi: 10.1177/000331979204301006. PMID: 1476271. 13: Yamanaka S, Miura K, Yukimura T, Okumura M, Yamamoto K. Putative mechanism of hypotensive action of platelet-activating factor in dogs. Circ Res. 1992 May;70(5):893-901. doi: 10.1161/01.res.70.5.893. PMID: 1568300. 14: Imanishi M, Ohta M, Akabane S, Kawamura M, Matsushima Y, Kojima S, Kuramochi M, Kimura K, Takamiya M, Ito K, et al. Aspirin injection test to predict angioplasty outcome in unilateral renovascular hypertension: preliminary report. Clin Invest Med. 1991 Dec;14(6):566-73. PMID: 1838974. 15: Imanishi M, Ohta M, Kawamura M, Akabane S, Matsushima Y, Kuramochi M, Kojima S, Kimura K, Takamiya M, Ito K, et al. Aspirin test for differentiation of unilateral renovascular hypertension from hyperreninemic essential hypertension. Am J Hypertens. 1991 Sep;4(9):761-8. doi: 10.1093/ajh/4.9.761. PMID: 1930860. 16: Miyawaki T, Yao H, Koyama E, Maeda S. Prevention of postanesthetic shivering with intravenous administration of aspirin. J Anesth. 1991 Apr;5(2):123-7. doi: 10.1007/s0054010050123. PMID: 15278644. 17: Takashio T, Yamashita H, Onodera S. [Effects of beta-adrenoceptor-related agents on hypoxic pulmonary vasoconstriction and relation with cyclic AMP and prostaglandins]. Nihon Kyobu Shikkan Gakkai Zasshi. 1991 Mar;29(3):322-31. Japanese. PMID: 1676767. 18: Ito S, Oka R, Tsuchida A, Yoshioka H. Disposition of single-dose intravenous and oral aspirin in children. Dev Pharmacol Ther. 1991;17(3-4):180-6. doi: 10.1159/000457520. PMID: 1841835. 19: Akabane S, Yoshimi H, Yoshida K, Kawano Y, Ashida T, Kinoshita O, Matsushima Y, Kawamura M, Imanishi M, Kuramochi M, et al. Differential effects of endothelin-1 and big endothelin on canine kidneys. J Cardiovasc Pharmacol. 1991;17 Suppl 7:S302-4. doi: 10.1097/00005344-199100177-00086. PMID: 1725363. 20: Hatano Y, Arai T, Noda J, Komatsu K, Shinkura R, Nakajima Y, Sawada M, Mori K. Contribution of prostacyclin to D-tubocurarine-induced hypotension in humans. Anesthesiology. 1990 Jan;72(1):28-32. doi: 10.1097/00000542-199001000-00006. PMID: 2105067.